These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 29802693

  • 1. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
    Arab M, Jamdar F, Sadat Hosseini M, Ghodssi- Ghasemabadi R, Farzaneh F, Ashrafganjoei T.
    Asian Pac J Cancer Prev; 2018 May 26; 19(5):1319-1324. PubMed ID: 29802693
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC.
    Int J Gynecol Cancer; 2008 May 26; 18(4):621-8. PubMed ID: 17868339
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F, Scaletta G, Capriglione S, Montera R, Luvero D, Lopez S, Gatti A, De Cicco Nardone C, Terranova C, Angioli R.
    Int J Gynecol Cancer; 2017 May 26; 27(4):696-702. PubMed ID: 28406844
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
    Baek MH, Lee SW, Park JY, Rhim CC, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.
    Int J Gynecol Cancer; 2017 Mar 26; 27(3):420-429. PubMed ID: 28187098
    [Abstract] [Full Text] [Related]

  • 17. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb 26; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 18. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Ren B, Guo W, Chen X.
    J Ovarian Res; 2016 Dec 02; 9(1):85. PubMed ID: 27912779
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree TS, Dusane R, Bajpai J, Ghosh J, Gulia S, Deodhar K, Menon S, Popat P, Sable N, Thakur M, Kerkar R.
    Indian J Cancer; 2018 Dec 02; 55(1):50-54. PubMed ID: 30147093
    [Abstract] [Full Text] [Related]

  • 20. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
    Angioli R, Capriglione S, Aloisi A, Ricciardi R, Scaletta G, Lopez S, Miranda A, Di Pinto A, Terranova C, Plotti F.
    Ann Surg Oncol; 2015 Dec 02; 22(13):4217-23. PubMed ID: 25808099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.